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Abstract
To identify aggressiveness-associated molecular mechanisms and biomarker candidates in bladder cancer, we performed a
SILAC (Stable Isotope Labelling by Amino acids in Cell culture) proteomic analysis comparing an invasive T24 and an
aggressive metastatic derived T24T bladder cancer cell line. A total of 289 proteins were identified differentially expressed
between these cells with high confidence. Complementary and validation analyses included comparison of protein SILAC
data with mRNA expression ratios obtained from oligonucleotide microarrays, and immunoblotting. Cul3, an overexpressed
protein in T24T, involved in the ubiquitination and subsequent proteasomal degradation of target proteins, was selected for
further investigation. Functional analyses revealed that Cul3 silencing diminished proliferative, migration and invasive rates
of T24T cells, and restored the expression of cytoskeleton proteins identified to be underexpressed in T24T cells by SILAC,
such as ezrin, moesin, filamin or caveolin. Cul3 immunohistochemical protein patterns performed on bladder tumours
spotted onto tissue microarrays (n = 284), were associated with tumor staging, lymph node metastasis and disease-specific
survival. Thus, the SILAC approach identified that Cul3 modulated the aggressive phenotype of T24T cells by modifying the
expression of cytoskeleton proteins involved in bladder cancer aggressiveness; and played a biomarker role for bladder
cancer progression, nodal metastasis and clinical outcome assessment.
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Introduction
Bladder cancer represents the 4th most common malignancy
among men and the 8th most frequent cause of male cancer
deaths [1]. Clinically, approximately 75% of transitional cell
carcinomas (TCC) are non-muscle invasive (TIS, Ta, and T1),
20% muscle infiltrating (T2–T4), and 5% metastatic at the time
of diagnosis [1]. Low-grade tumors are papillary and usually
non-invasive, while high-grade tumors can be either papillary or
non-papillary, and often invasive. Patients diagnosed with
localized TCC have a 5-year survival rate above 90%.
However, patients with regional and distant metastatic disease
have a 5-year survival rate below 50% and 10%, respectively
[1]. Bladder cancer progression follows complex sequential
steps, not completely understood [2–4]. Differences in aggres-
siveness behaviour have been described between the invasive
T24 bladder cancer cell line and the more aggressive T24T
variant that develops metastases after tail vein injection [5–9].
Identification of differentially expressed proteins between these
cells might uncover molecular mechanisms associated with
tumor aggressiveness in vitro potentially leading to metastasis.
Proteins participating in such pathways could serve as
biomarkers for either early identification of aggressive outcome
and/or potentially be therapeutically targetable.
Quantitative proteomics contributes to the discovery of
candidate disease-specific target and biomarkers. While protein
and antibody arrays permit differential quantification of known
proteins [10,11], mass spectrometry techniques lead for protein
identification [12]. Stable isotope labelling by amino acids in cell
culture (SILAC) involves the addition of (12)C- and (13)C-labeled
amino acids to growth media of separately cultured cells, giving
rise to cells containing "light" or "heavy" proteins, respectively
[12–31]. To our knowledge, SILAC has not been reported in
bladder cancer. Here, a quantitative proteomic analysis was
applied to T24 and T24T cells to identify proteins and pathways
related to their differential aggressiveness following our experi-
mental design (Figure 1).
Materials and Methods
1. Functional analysis of T24 and T24T bladder cancer
cells
Cell culture. T24 was obtained from the American Type
Culture Collection and cultured as previously described [32,33].
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T24T was derived from T24 at Dr Theodorescu’s laboratory [5–
9]. Cells were grown for 4–6 passages and harvested at 75%-90%
confluency. Cell pellets were washed three times in cold PBS, and
frozen at -20uC before RNA and protein extraction.
Proliferation assay
1.2x104 cells per well were seeded in 96-well plates in triplicate
in DMEM containing 10% FBS. After culturing for 24, 48, 72 and
96 hours, proliferation was measured with the MTT assay (Roche,
Mannheim, Germany).
Wound healing assay. 3.5x105 cells were seeded in 6-well
plates, and a wound was made in the monolayer using a sterile
pipette tip once the cells reached confluency. Photographs of cells
invading the wound were taken at the indicated times.
Invasion assay. Cell culture 24-well plates inserts (pore size
8 mm, BD Biosciences, San Jose´, CA) were seeded with 2.5x104
T24 and T24T cells, and also with T24T cells after 24 and 48
hours post-transfection with Cul3 siRNA (50 nM) in 500 mL of
DMEM medium with 0.1% FBS in the upper chamber. Medium
with 10% FBS (500 mL) was added to the lower chamber as a
chemotactic agent. Matrigel invasion chambers (BD) were
maintained for 24 hours in a humidified incubator at 37uC, 5%
CO2 atmosphere. Cells on both sides of the matrigel chamber
were fixed with 4% paraformaldehyde for 10 minutes, washed
with PBS, stained with 1mg/mL 4’-6-Diamidino-2-phenylindole
(DAPI: Sigma, St Louis, MO) for 10 minutes, and analysed by
confocal microscopy (Leica TCS-SP5, Wetzlar, Germany). The
number of invading cells was assessed with the Imaris software (Bit
Plane, Zurich, Switzerland), estimating the percentage of invasion
as: number of invading cells/number of total cells6100.
Cul3 silencing. Cul3 knocked-down was performed in T24T
by transient transfection with Lipofectamine (Invitrogen, Carls-
bad, CA) using control (not-targeting) small interfering double-
stranded RNA (siRNA) and the smart pool siRNA targeted against
Cul3 (both from Dharmacon, Waltham, MA). Cul3 silencing
transfectants exposed to 50nM and 100Nm of targeted siRNA
were collected at 24h and 48h for proliferation, migration or
Figure 1. Cell line phenotypes and experimental design. Functional analyses were performed to assess the differential aggressive phenotype
of T24 and T24T bladder cancer cells on: A) proliferation, B) invasion, and C) migration. The average of duplicate experiments for each functional
assay of these cells at several timepoints is represented in each panel. D) Schematic diagram showing the workflow used for the multiplexed SILAC-
based experiments. Internal labelling was performed in vitro, the protein extracts were fractionated via SDS-PAGE, digested with trypsin in gel, and
tryptic digests were analyzed by LC-MS/MS to both identify and quantify the proteins present. E) Comparison of the protein changes identified by
SILAC was performed with those observed by oligonucleotide arrays. F) Validation of the protein changes identified by SILAC in Western blots of
protein extracts obtained from T24-T24T cells. G) Immunohistochemistry on tissue arrays containing bladder tumors served to validate associations
of identified proteins with clinicopathological variables in bladder cancer. H) siRNA silencing of identified proteins and subsequent functional
analyses and immunoblotting validation served to evaluate the impact of identified candidates on the aggressive phenotype of T24T and the
regulation of other differentially expressed proteins identified by SILAC.
doi:10.1371/journal.pone.0053328.g001
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invasion assays, as described above. Cul3 silencing was confirmed
by immunoblotting.
2. SILAC protein profiling
Cell Culture and Metabolic Labeling. T24 and T24T cells
were maintained in lysine and arginine-depleted DMEM (Milli-
pore, Billerica, MA) supplemented with 10% dialyzed FBS
(Invitrogen, Carlsbad, CA), 100 units/mL of penicillin/strepto-
mycin (Invitrogen) and either naturally-occurring isotope abun-
dances (‘‘light’’) (T24) or stable isotope-labelled (‘‘heavy’’) 13C6
lysine and 13C6 arginine amino acids (Cambridge Isotope Labs,
Andover, MA) (T24T). Culture media were refreshed every 2 days
by removing half of the volume present on each plate and
replacing it with fresh medium. Cells were grown for at least 6
doublings to allow full incorporation of labelled amino acids. Two
large-scale SILAC replicates (26107 cells per condition) were
performed. Complete incorporation of 13C-Arg and 13C-Lys into
T24 and T24T cells after six cell divisions in isotopically heavy
medium (direct and reverse labeling) was verified by MS of a
protein digest.
Protein Fractionation. To reduce the complexity of the
sample, a nuclear/cytosol fractionation was performed. Cells were
lysed in a lysis buffer (20 mM HEPES, pH 7.0, 10 mM KCl,
2 mM MgCl, 0.5% Nonidet P40, 1 mM Na3VO4, 1 mM PMSF,
0.15 U mL-1 aprotinin) and homogenized by 30 strokes in a
Dounce homogenizer. The homogenate was centrifuged at
1,500 g for 5 min to sediment the nuclei. The supernatant was
then resedimented at 15,000 g for 5 min, and the resulting
supernatant formed the non-nuclear or cytosol fraction. The
nuclear pellet was washed three times and resuspended in the
same buffer containing 0.5 M NaCl. The extracted material was
sedimented at 15,000 g for 10 min and the resulting supernatant
was termed the nuclear fraction.
SDS-PAGE and in-gel digestion. Proteins in cytosolic and
nuclear fractions were separated by SDS-PAGE on 10% SDS-
polyacrylamide gels. A total of 80 mg of protein was loaded per
lane. After electrophoresis, proteins were visualized by Coomassie
blue staining and the gel lane was cut horizontally into 20 sections.
Excised gel bands were cut into small pieces and destained in
50:50 25 mM ammonium bicarbonate/acetonitrile, dehydrated
with acetonitrile and dried. Gel pieces were rehydrated with 30 mL
of 12.5 ng/mL trypsin solution in 25 mM ammonium bicarbonate
and incubated overnight at 37uC. Peptides were extracted using
acetonitrile and 5% formic acid, dried by vacuum centrifugation
and resuspended in 15 mL of 2% acetonitrile in 0.1% formic acid.
All samples were sonicated for 10 min before MS analysis.
Nanoflow LC-MS/MS. The peptide mixture from in-gel
tryptic digestions (using 30 mL of trypsin at 12.5 ng/mL) was
analyzed using nanoflow LC-MS/MS. Peptides were loaded onto
a trap column (Reprosil C18, 3 mm particle size, 0,3610 mm,
120 A˚ pore size, SGE) and then eluted to the analytical column
(Acclaim PepMap 100, C18, 3 mm particle size, 75 mm615 cm,
100 A˚ pore size, Dionex, LC Packings) with a linear gradient of 5–
80% acetonitrile in 0.1% formic acid. Sample was delivered over
120 min by a nano-LC ultra 1D plus system (Eksigent) at a
200 nL/min flow-rate to a stainless steel nano-bore emitter (OD
150 mm, ID 30 mm, Proxeon, Odense, Denmark). Peptides were
scanned and fragmented with an LTQ XL linear ion trap mass
spectrometer (Thermo, San Jose, CA) operated in data-dependent
ZoomScan and MS/MS switching mode using the three most
intense precursors detected in a survey scan from 400 to 1600 u
(three mscans). ZoomScan mass window was set to 12 Da enabling
monitoring of the entire 12C/13C isotopic envelope of most doubly
and triply charged peptides. Singly charged ions were excluded for
MS/MS analysis. Normalized collision energy was set to 35% and
dynamic exclusion was applied during 3 min periods to avoid
repetitive fragmentation ions.
Protein identification and quantitation. Generated .raw
files were converted to .mgf files for MASCOT database search. A
database containing the NCBInr Homo Sapiens sequences
containing 34180 protein entries (as of 04-03-2008) was searched
using MASCOT Software (version 2.3 Matrix Science) for protein
identification. Search criteria included trypsin specificity with one
missed cleavage allowed, and methionine oxidation, 13C-Arg and
13C-Lys as variable modifications. A minimum precursor frag-
ment-ion mass accuracy of 1.2 and 0.3 Da, respectively, and a
requirement of at least two bold red (unique peptides) per protein
were required for protein quantitation. Cut-off values for
MASCOT scores of peptides and proteins were set to 39
(p,0.05) and 46 (p,0.01), respectively, to consider them as
accurate identifications. The false positive rate was calculated
searching the same spectra against the NCBInr Homo Sapiens
decoy randomized database. Relative quantification ratios of
identified proteins were calculated using QuiXoT (version 1.3.26).
SILAC T24T/T24 ratios were defined by the intensities of the
heavy peptides (C13) divided by the intensities of the light peptides
(C12). Protein ratios obtained by QuiXoT were manually verified
for all peptides. A proportion of 13C6-Arg was converted to
13C5-
Pro leading to a reduction in the intensity of the isotope-labeled
peptide peak; this was corrected for all peptides containing one or
more proline residues by adding the intensity found for the peptide
containing 13C6-Arg
13C5-Pro or
13C6-Lys
13C5-Pro to the
intensity of the peak containing only 13C6-Arg or
13C6-Lys. A
combined list of proteins identified in all experiments was
condensed at 80% homology using the ProteinCenter software
package (Proxeon Bioinformatics AS, Odense, Denmark) to
remove redundant IDs such as human orthologous sequences,
redundant database entries, and indistinguishable isoforms based
on observed peptide coverage. Subcellular localization and
functional processes of the proteins identified by SILAC were
assigned based on the biological knowledge available in Gene
Ontology (GO) annotations. The Ingenuity Pathway (IPA)
software was also used to provide insight into biological networks
[33,34].
3. Gene Expression Profiling with Oligonucleotide Arrays
RNA extraction. Total RNA was isolated using TRIzol (Life
Technologies, Carlsbad, CA) followed by RNeasy purification.
RNA quality was evaluated based on 260:280 ratios of
absorbance, and integrity was checked by gel electrophoresis
using the 2100 Bioanalyzer (Agilent, Palo Alto, CA) [32,34].
Gene arrays. Complementary DNA was synthesized by
in vitro transcription from 1.5 mg of the total RNA purified using
a T7-oligo(dT) Promoter Primer Assay (Affymetrix, Santa Clara,
CA), labeled with biotinylated nucleotides (Enzo Biochem, Farm-
ingdale, NY), and hybridized to test GeneChips (Affymetrix), to
assess sample quality before hybridizing onto the U133A human
GeneChips containing 22,283 probes representing known genes
and expression sequence tags (Affymetrix) [34].
Data analysis. Scanned image files were visually inspected
for artifacts and analyzed using the Affymetrix Microarray Suite
5.0 (MAS 5.0). Differential expression was evaluated using signal
as the main response measure extracted for each gene in every
sample, as determined by the default settings of the MAS 5.0.
Correlations between gene and protein ratios were analyzed using
Kendall’s tau test. To compare SILAC and oligonucleotide arrays
results, the cumulative probability of expected and observed results
were represented over the range of differential expression ratios.
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4. Validation by immunoblotting
Total protein was extracted from bladder cancer cells using
RIPA lysis buffer and quantified with the Bradford assay using
BSA as standard (Protein Assay, Bio-Rad, Hercules, CA). Total
protein extracts (50 mg) were mixed with 5x SDS sample buffer
(62.5 mM TrisHCl [pH 6.8], 2% SDS, 10% glycerol, 5% b-
mercaptoethanol, 0.005% bromophenol blue) and resolved by
SDS-PAGE on 10% acrylamide gels. Proteins were electro-
transferred onto PVDF membranes (Millipore, Bedford, MC)
and activation with methanol. Membranes were blocked with
5% non-fat dry milk in PBS and 0.1% Tween-20 for 1 hour at
room temperature and incubated overnight at 4 uC with
primary antibodies against: Annexin2 (39 kDa, mouse, 1:2000,
#610068, BD Transduction Laboratories, San Jose´, CA US),
Bcas2 (26 kDa, mouse, 1:6000, #H00010286-M01, Abnova,
Heidelberg, Germany), L-Caldesmon (80kDa, mouse, 1:100,
#C56520, BD Transduction Laboratories), calreticulin (48 kDa,
rabbit, 1:5000, #C4606, Sigma, St. Louis, MO, US), Caveolin1
(20–22 kDa, mouse, 1:100, #C37120, BD Transduction Labo-
ratories), cdc2 (34 kDa, rabbit, 1:1000, #sc-954, Santa Cruz,
Santa Cruz, CA, US), CD44 (80 kDa, mouse, 1:50, #NCL-
CD44v3, Novocastra, Wetzlar, Germany), Copine3 (38 kDa,
rabbit,1:100, kindly supplied by Dr. Piris, located at CNIO,
Madrid, Spain), Cul3 (89 kDa, rabbit, 1:100, #RB1575PCS,
NeoMarkers, Fremont, CA, US), Cytokeratin18 (48 kDa,
mouse, 1:100, #IF14, Oncogene-MERCK, Darmstad, Ger-
many), DDX21 (87 kDa, rabbit,1:3500, #10528-1-AP, Protein-
tech, US), DNMT1 (183 kDa, mouse, 1:100, #IMG-261,
IMGENEX, San Diego, CA, US), Dynactin p50 (44 kDa,
mouse,1:100, #D74620, BD Transduction Laboratories), Dyna-
min (mouse, 97 kDa, 1:5000, #D25520, BD Transduction
Laboratories,), EGFR (175 kDa, mouse, 1:100, #GRO1,
Oncogene-MERCK), Ezrin (80 kDa, mouse, 1:7000, #E8897,
Sigma), Filamin A (250 kDa, mouse, 1:50, #NCL-FIL,
Novocastra, UK), gelsolin (47 kDa, mouse,1:100, #G4896,
Sigma), HSP70 (70 kDa, mouse, 1:200, #SC-66048, Santa
Cruz), importin 9 (116 kDa, goat, 1:100, sc-103567, Santa
Cruz), MCM6 (92 kDa, rabbit, 1:200, kindly supplied by Dr.
Mendez, located at CNIO, Madrid, Spain), MAPK-4 (65 kDa,
rabbit,1:1000, sc-68169, Santa Cruz), Moesin (68–77 kDa,
mouse,1:50, #MS-727-P0, NeoMarkers), MSH6 (152 kDa,
mouse,1:200, #610918, BD transduction Laboratories), Nucleo-
phosmin/B23 (32kDa, mouse, 1:5000, #18-7288, Zymed, SF,
CA, US), NUP133 (133 kDa, mouse,1:500, #SC-101290, Santa
Cruz), Rab14 (23 kDa, rabbit, 1:100, #PRO-873, Avivasybio,
San Diego, CA), RCC1 (44 kDa, goat, 1:300, #SC-1161, Santa
Cruz), VDAC (30 kDa, rabbit, 1:100, #4866, Cell Signaling,
Beverly, MA). Blots were washed in PBS and 0.1% Tween-20,
and incubated with horseradish peroxidase-conjugated second-
ary antibodies for 1 h at room temperature: anti-mouse
(1:1000), anti-rabbit (1:2000) and anti-goat (1:2000, all Dako,
Glostrup, Denmark). Antibody binding was visualised using an
enhanced chemiluminescent immunoblotting detection system
(ECL, GE Healthcare). a-tubulin (50kDa, mouse, 1:4000,
#T5168, Sigma) was used as loading and normalizing control.
Immunoblots were scanned and analyzed using the ImageJ1.43u
software (Wayne Rasband, National Institute of Health).
5. Clinical evaluation of the expression of metastases
related biomarkers
Tissue samples and microarrays. Seven custom-made
bladder cancer tissue microarrays were constructed at the Tumor
Markers Group including triplicate or quadriplicate cores
(1.0 mm) of primary bladder tumors (n = 284) following random-
ized designs. Paraffin-embedded tumors for tissue array construc-
tion were collected and handled anonymously following ethical
and legal protection guidelines of human subjects after written
consent approval and Institutional Review Board (IRB) approved
protocols corresponding to the research project SAF2009-13035 at
collaborating institutions: Fundacio Puigvert and Hospital Central
de Asturias. Demographic information indicated the presence of
251 males and 33 females, with a median age of 66.0 years
(range:25–81). Tumor stage distribution was: pT1 (n = 87), pT2
(n = 121), pT3 (n = 48) and pT4 (n = 28), and tumor grade
distribution was: low-grade (n = 58) and high-grade (n = 226),
defined according to consensus criteria [35]. Two of these tissue
microarrays including a set of 71 muscle-invasive (pT2+) high
grade TCC bladder tumors with known lymph node metastatic
status (N0 = 37, N+= 34). Clinicopathologic and annotated follow-
up information allowed associations of Cul3 with histopathology
and outcome.
Immunohistochemistry. Protein expression of Cul3 was
assessed by immunohistochemistry on tissue microarrays using
avidin-biotin immunoperoxidase procedures. Antigen retrieval
(0.01% citric acid for 15 minutes under microwave) was employed
prior to incubation overnight at 4 uC with the Cul3 rabbit
antibody used in immunoblotting (1:300 dilution). Antibody
binding was detected with a biotinylated goat anti-rabbit
secondary antibody (1:1000, Vector Laboratories). Absence of
primary antibody was used as negative control. Testis was utilized
as positive control. Diaminobenzidine was utilized as the final
chromogen and hematoxylin as the nuclear counterstain [32–34].
Statistical Analysis. Means of findings from two indepen-
dent observers of all cores from each tumor sample arrayed
were used for statistical analyses. Associations of Cul3 expression
by immunohistochemistry with histopathologic stage and tumor
grade were evaluated using the non-parametric Wilcoxon-
Mann-Whitney and Kruskall-Wallis tests [36]. Cul3 expression
was evaluated as a continuous variable based on the number of
cells expressing the protein in the nucleus. The intensity of the
staining was categorized as negative (2) to low (+), intermediate
(++) and high (+++). In addition to the intracellular localization,
it was also evaluated whether the protein was present or not in
the extracellular matrix surrounding neoplastic cells. Cul3 cut-
off level for prognostic evaluation was selected on the basis of
median expression values among groups under analyses.
Association of Cul3 with disease-specific survival was evaluated
using the log-rank test in cases with available follow-up. Disease-
specific survival time was defined as the months elapsed
between transurethral resection or cystectomy and death as a
result of disease (or the last follow-up date). Patients alive at the
last follow-up or lost to follow-up were censored. Survival curves
were plotted using Kaplan-Meier methodology [36]. Statistical
analyses were performed using SPSS statistical package (version
17.0).
Results
Functional analyses in vitro
Several aggressiveness aspects of T24-T24T cells were initially
analysed. T24T had significant higher proliferation rates than
T24 at the four time points studied (p,0.05, Figure 1A).
Invasion assays indicated that T24 were on average 50% less
invasive than T24T cells at 48h (Figure 1B). Wound healing
assays revealed significantly faster migration rate for T24T
(Figure 1C). In vitro assays suggested that T24T cells had more
aggressive phenotypes.
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Changes in protein abundance between T24 and T24T
cells using SILAC
A total of 1830 proteins were identified in the two SILAC
experiments, from which 831 were simultaneously identified in
both replicates and passed the criteria established for protein
quantitation. The overall false discovery rate was 2.1% being
estimated by the number of hits against the reverse sequence/total
hits (p,0.01). The mean relative standard deviation (SD) of the
ratios obtained from replicates was 0.24, indicating good
agreement between experiments.
Regarding SILAC ratios distribution, most of the proteins
identified were within the SILAC ratio range between 1.5 and
0.67, as expected when analysing closely related cell lines in a 1:1
protein mixture (Figure 2A). Using 1.5 as the threshold ratio, 289
proteins were differentially expressed between the two cell lines, 88
of which were more abundant in T24T. Among the 289
differentially expressed proteins (Table S1), Table 1 includes those
proteins previously related to bladder cancer metastases, and those
validated by immunoblotting. The full list of proteins identified in
both replicates (n = 831) using SILAC is in Table S2.
Functional classification of the proteins identified
The functional annotation of the 289 differentially expressed
proteins in T24 and T24T cells was initially assigned using the
Protein Center software. Three main types of annotations were
obtained from GO consortium website: cellular components,
molecular functions, and biological processes (Figure 2B, C, D). A
GOslim approach defined specifically for ProteinCenter reduced
the multiple GO annotations to a manageable set of approxi-
mately 20 high-level terms that were used to filter the information
into percentage estimations. Major molecular functions included
protein binding (78%) or catalytic activity (67%). Metabolic
processes (84%) and cellular organization and biogenesis (54%)
were frequent biological processes. Protein annotation distribution
supported the in vitro functional assays described above linking
cellular reorganization with migration and invasion phenotypes
(Figure 1). A high number of proteins localized to the cytoplasm
(87%) was found as compared to the nucleus (48%). This
observation led us to focus on proteins that could play a relevant
role in cytoskeletal reorganization and the aggressive phenotype of
T24T.
Figure 2. A) Distribution of SILAC T24T/T24 ratios: The log of the SILAC ratio for each protein (n =2) represents the difference in
relative expression between highly metastatic (T24T) and invasive (T24) bladder cancer cells. Proteins were sorted and plotted by SILAC
ratio. As expected for a 1:1 mixture, most proteins showed a SILAC ratio within the 1.5 and 0.67 cutoffs. Classification of the proteins identified based
on their functional annotations using the Gene Ontology: B) Molecular function, C) Biological processes and D) Cellular components. These analyses
were performed with the 289 proteins found to be differentially expressed. When more than one assignment was available for a given protein, all the
functional annotations were considered in the analyses. These classifications were redundant (over 100%) as proteins could be annotated in more
than one assignment.
doi:10.1371/journal.pone.0053328.g002
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Table 1. Selected proteins with altered abundance in bladder cancer metastatic T24T versus T24 cells.
Accession
number
(gi) Protein Name
Common
name/
Abbreviation
Molecular
weight
(Kda)
Gene Array
T24T/T24
Ratio
SILAC
T24T/T24
Ratio SD1
4507951 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, eta polypeptide
YWHAH 30 0.92 9.44 0.09
122939159 peptidyl arginine deiminase, type II PADI2 75 – 8.35 0.69
41872631 fatty acid synthase FASN 273 – 3.85 0.14
4504165 gelsolin isoform a precursor GSN* 90 10.20 3.61 0.73
32171238 BAI1-associated protein 2-like 1 BAIAP2L1 56 – 3.03 0.05
4505591 peroxiredoxin 1 PRDX1 22 – 2.88 0.13
148298764 hydroxymethylglutaryl-CoA synthase 1 HMGCS1 57 1.17 2.83 0.25
38569421 ATP citrate lyase isoform 1 ACLY 120 10.74 2.54 0.17
10864011 sulfide dehydrogenase like SQRDL 50 – 2.50 0.13
4507835 uridine monophosphate synthase UMPS 52 1.18 2.34 0.20
4503165 cullin 3 Cul3* 89 1.00 2.26 0.18
4504169 glutathione synthetase GSS 52 1.12 2.24 0.20
4503377 dihydropyrimidinase-like 2 DPYSL2 67 1.15 2.19 0.18
29789090 regulator of chromosome condensation 2 RCC2 56 – 2.19 0.28
20127454 5-aminoimidazole-4-carboxamide ribonucleotide
formyltransferase/IMP cyclohydrolase
ATIC 64 – 2.15 0.20
21361709 regulation of nuclear pre-mRNA domain containing 1A RPRD1A 35 – 2.09 0.25
47933397 lanosterol synthase LSS 83 – 2.06 0.18
39777597 transglutaminase 2 isoform a TGM2 77 1.04 2.01 0.04
116734860 amylo-1, 6-glucosidase, 4-alpha-glucanotransferase isoform 1 AGL 174 11.93 1.95 0.17
14150139 within bgcn homolog isoform 1 WIBG 22 – 1.94 0.06
20070384 phosphoglycerate mutase family member 5 PGAM5 32 – 1.92 0.18
4506903 splicing factor, arginine/serine-rich 9 SFRS9 25 1.04 1.9 0.05
gi|48255933 high-mobility group nucleosome binding domain 1 HMGN1 10 – 1.87 0.13
24308013 peptidase (mitochondrial processing) alpha PMPCA 16 – 1.84 0.10
21361659 importin 9 IPO9* 116 1.09 1.83 0.17
29725609 epidermal growth factor receptor isoform a precursor EGFR* 175 9.96 1.82 0.12
26051235 nucleoporin 133kDa NUP133* 133 1.06 1.78 0.21
4507877 vinculin isoform VCL VCL 123 0.09 0.67 0.03
48255935 CD44 antigen isoform 1 precursor CD44* 80 0.83 0.66 0.06
4504047 GNAS complex locus GNASL GNAS 45 1.03 0.61 0.08
161702986 Ezrin EZR* 80 0.72 0.58 0.04
4504183 glutathione transferase GSTP1 23 0.94 0.58 0.05
103472005 antigen identified by monoclonal antibody Ki-67 MKI67 358 – 0.56 0.05
4505257 Moesin MSN* 68–77 0.89 0.54 0.04
55770844 catenin, alpha 1 CTNNA1 100 1.01 0.47 0.01
50845388 annexin A2 isoform 1 ANXA2* 39 0.97 0.42 0.04
4503015 copine III CPNE3* 38 0.96 0.40 0.05
116063573 filamin A, alpha isoform 1 FLNA* 250 0.92 0.38 0.04
5031815 lysyl-tRNA synthetase isoform 2 KARS 68 1.04 0.31 0.03
156071459 solute carrier family 25, member 5 SLC25A5 35 0.98 0.30 0.06
19920317 cytoskeleton-associated protein 4 CKAP4 66 – 0.28 0.04
33620775 kinectin 1 isoform a KTN1 14 1.03 0.26 0.04
209862851 plastin 3 PLS3 16 0.01 0.26 0.02
71773415 annexin VI isoform 2 ANXA6 75 0.90 0.24 0.01
105990514 filamin B, beta (actin binding protein 278) FLNB 278 – 0.23 0.03
116805322 gamma filamin isoform a FLNC 291 0.75 0.23 0.04
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Comparison of gene and protein expression ratios
SILAC protein expression ratios were compared with mRNA
expression provided by oligonucleotide microarrays for the
candidates identified by both methods (n = 438) (Table 1, Table
S3). A positive correlation coefficient (Kendalls tau) of 0.206
(p,0.0005) was obtained (Figure S1A). Importantly, the median
SILAC protein expression ratio was 0.98 for these candidates
(range: 0.16–9.44), which was similar to the median of 1.02
observed for oligonucleotide arrays (range: 0.01–100.80). Exclud-
ing two outliers detected by both techniques increased the
correlation coefficient to 0.210 (p,0.0005, N = 438: Figure
S1B). To interpret the differences between the expected and the
observed correlations between RNA and protein expression, the
cumulative probability of the observed ratio for differential
expression was represented against the expected ratio for both
techniques (Figure S1C, D). The figures highlighted the wider
ranges of differential expression observed in oligonucleotide arrays
when compared to the same candidates in SILAC analyses.
Validation of SILAC identified candidates using
immunoblotting
To validate SILAC expression ratios of proteins identified in
both replicates, immunoblotting was performed (Figure 3).
Increased expression in T24T was observed for gelsolin, Cul3,
importins, nucleoporins and EGFR, and decreased expression was
found for ezrin, moesin, filamin, caveolin or CD44, among others.
Immunoblots were quantified to correlate with expression ratios
obtained by SILAC and in gene arrays. Based on the good
agreement of these observations for Cul3, a protein known to be
involved in the ubiquitination and subsequent degradation of
target proteins, it was selected for further analyses to: a) evaluate its
clinical relevance as a biomarker candidate to assess aggressive
clinical behaviour, and b) to evaluate Cul3 impact on the
aggressive phenotype of T24T and on modulating expression of
other differentially expressed proteins identified by SILAC. Figure
S2 showed the additional validation by immunoblots of candidates
differentially expressed in T24T cells in oligonucleotide arrays that
were not quantified by SILAC, and vice versa, for which antibodies
were available. We did not observe major differences in
experimental molecular weights as compared to predicted sizes.
Molecular pathways associated with aggressiveness
To understand the mechanisms by which differentially ex-
pressed proteins contribute to bladder cancer aggressiveness, the
dataset containing the differentially expressed proteins (N = 289)
was uploaded into the IPA software. An interaction map grouped
31 of the differentially expressed proteins to which Cul3 was added
(Figure S3). An independent analysis was performed importing the
top ten selected differentially expressed proteins in both SILAC
and gene arrays, and validated in immunoblots (Figure S4). This
analysis highlighted that validated proteins contributing to this
network participated in the following critical neoplastic-related
annotated biological functions: cellular assembly and organization,
cancer, cell movement, cell morphology, and cell function and
maintenance.
Cul3 is differentially expressed in bladder tumors and
associated with bladder cancer aggressiveness
Protein expression patterns of Cul3 by immunohistochemistry
were optimized and assessed on tissue arrays. Differential
expression was observed for Cul3 among the bladder tumors
tested. Significant statistical associations were found between
Cul3 nuclear over-expression and increasing tumor stage when
comparing non-invasive (Figure 4A) versus muscle-invasive
(Figure 4B) bladder tumors (p = 0.001, n = 284). Moreover,
Cul3 over-expression was associated with poor disease-specific
survival (log-rank, p = 0.002), (Figure 4C). Primary invasive
bladder tumors that developed lymph node metastases showed
higher expression levels of Cul3 as compared to those with
negative lymph nodes (p = 0.025). A high intensity and the
presence of Cul3 in the extracellular matrix were also associated
with increasing stage (p = 0.004, and p = 0.005, respectively), and
with the presence of lymph node metastasis (p = 0.002, and
p = 0.001). These observations indicated that Cul3 over-expres-
sion could be associated with tumor staging and the metastatic
phenotype. Overall, expression patterns of Cul3 in bladder
Table 1. Cont.
Accession
number
(gi) Protein Name
Common
name/
Abbreviation
Molecular
weight
(Kda)
Gene Array
T24T/T24
Ratio
SILAC
T24T/T24
Ratio SD1
4507813 UDP-glucose dehydrogenase UGDH 55 9.11 0.23 0.03
16753203 ubiquilin 1 isoform 1 UBQLN1 62 – 0.22 0.01
15451856 caveolin 1 CAV1* 20–22 0.96 0.21 0.04
7305053 myoferlin isoform a MYOF 234 – 0.21 0.05
156104878 Glutaminase GLS 73 1.05 0.20 0.03
42734430 polymerase I and transcript release factor PTRF 43 – 0.20 0.03
157694492 MYB binding protein 1a isoform 2 MYBBP1A 133 1.12 0.20 0.14
63252913 gelsolin-like capping protein CAPG 38 0.83 0.16 0.04
21071056 SWI/SNF-related matrix-associated actin-dependent regulator of
chromatin a4 isoform B
SMARCA4 184 0.74 0.16 0.08
5453555 ras-related nuclear protein RAN 24 – 0.07 0.11
All proteins were identified at .99% confidence (corresponding to a Mascot score .46). The table includes the accession number (gi), protein name, molecular weight
(in kD), gene array ratio, SILAC ratios (T24T/T24), and the standard deviation (SD, n = 2). All proteins were identified in the two SILAC replicates with at least two unique
peptides. Proteins previously described to be involved in cancer metastases are highlighted in italics, while those reported to be related to bladder cancer metastases
are highlighted in bold. Proteins validated in immunoblots are highlighted with an asterisk. The absence of values in the "Gene Array Ratio" column, highlighted as "-",
indicates absence of the specific probe on the array. The complete set of differentially expressed proteins identified is provided in Table S1.
doi:10.1371/journal.pone.0053328.t001
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tumors suggested its role as a biomarker for tumor stratification,
metastasis and clinical outcome prognosis.
Functional and immunoblotting analyses upon Cul3
silencing
The impact of knocking down Cul3 expression using siRNA at
50nM and 100nM in the aggressive phenotype of T24T cells was
assessed in vitro. Proliferation diminished at 24 and 48 hours after
Cul3 silencing (p,0.05) (Figure 5A). Wound healing assays
revealed the slower migration rate of T24T cells lacking Cul3
expression (Figure 5B). Invasion assays indicated that T24T cells
silenced for Cul3 were on average 50% less invasive at both time
points than the control siRNA (Figure 5C). Using Cul3 siRNAs at
100nM showed similar invasion rates as 50 nM (data not shown).
The impact of Cul3 silencing on the expression of other proteins
found differentially expressed by SILAC was tested by immuno-
blots (Figure 5D). Cul3 silencing restored the expression of
cytoskeleton adhesion proteins such as filamin A, ezrin, caveolin1
or moesin. Overall, functional analyses and immunoblotting
validation upon Cul3 silencing revealed that Cul3 modulated the
aggressive phenotype of T24T, and modified the expression of
cytoskeleton proteins also identified differentially expressed by
SILAC.
Discussion
A SILAC approach was designed to identify pathways
associated with bladder cancer aggressiveness. Cul3 was revealed
as a candidate contributing to the aggressive phenotype of T24T
modifying cytoskeleton remodelling and as a bladder cancer
biomarker correlating with poor outcome. Our comparative
functional analyses of T24-T24T were complementary and agreed
with previous in vitro results describing a more aggressive
phenotype of T24T cells. By contrast to earlier analyses [5], we
performed proliferation by seeding cells at a three-fold higher
density, plus wound healing and invasion assays. These data
highlighted the ability of T24T cells to grow on top of each other,
in contrast to the contact inhibition previously described for T24
cells. These results further suggested that T24T cells have a greater
potential for proliferation, motility and potentially to metastasize,
Figure 3. Verification of the expression of the proteins identified. (A) Validation of the SILAC results of selected proteins in immunoblots of
protein extracts from the bladder cancer cells analyzed. The results validated the expression levels of proteins identified by the proteomic approach,
including differentially and non-differentially expressed candidates. Antibodies displaying a single predominant band at the expected molecular
weights were accepted: and a-tubulin, was used as the loading control. GSN, Gelsolin; Cul3, Cullin 3; IPO9. Importin 9; EGFR, Epidermal Growth Factor
Receptor; NUP133, Nucleoporin 133; HSP70, Heat Shock Protein 70kDa; MCM6, Minichromosome Maintenance Complex Component 6; RCC1,
Regulator of Chromosome Condensation 1; BCAS2, Breast Carcinoma Amplified Sequence 2; DNM, Dynamin; NPM, Nucleophosmin; DCTN, Dynactin;
CALR, Calreticulin; MAPK, Mitogen-Activated Protein Kinase; DDX21, DEAD (Asp-Glu-Ala-Asp) box polypeptide 21; CDC2: Cell Division Cycle 2; DNMT1,
DNA (cytosine-5)-Methyltransferase 1; MSH6, MutS Homolog 6; RAB14, GTPase Rab14; VDAC, Voltage-Dependent Anion Channel; CK18, Cytokeratin
18; CALD, Caldesmon; CD44, CD44 antigen isoform 1 precursor 2; EZR, Ezrin; MSN, Moesin; ANXA2, Annexin A2; CPNE3, Copine 3; FLNA, Filamin A;
CAV1, Caveolin 1. Western Blots were scanned and analyzed using a-tubulin as normalizing control.
doi:10.1371/journal.pone.0053328.g003
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as demonstrated in vivo [6–9]. A high number of proteins were
found differentially expressed between T24-T24T, with biological
network annotations supporting the functional differences ob-
served in vitro. Furthermore, proteins were shown differentially
expressed using oligonucleotide arrays and by selected immuno-
blotting. Immunostaining of tissue arrays containing independent
series of bladder cancer patients served to assess the associations of
a selected protein, Cul3, with clinicopathological variables.
Functional analyses and immunoblotting validation upon Cul3
silencing highlighted its impact in the aggressive phenotype of
T24T cells and at modulating other cytoskeleton proteins
identified by SILAC. Thus, combination of -omic approaches,
functional and clinical analyses identified Cul3 as a novel
candidate related to bladder cancer aggressiveness.
The extent of the proteomic profile defined in this study was
comparable to other SILAC studies [13–29]. On the basis of the
identity and biological abundance of the proteins identified,
SILAC exhibited a satisfactory dynamic range in profiling both
high- and low-abundance proteins. The broad spectrum of
proteins observed reflects SILAC suitability for proteomic studies
of cancer cells. Subcellular fractionation reduced sample com-
plexity and increased the probability of detecting less abundant
proteins. The level of ambiguity for a protein ratio was estimated
taking into account the SDs within each protein because every
SILAC ratio was calculated as a mean of at least 2 peptide values
with their associated SDs. We selected 1.5 and 0.67 as cutoffs, also
frequently used in SILAC-related studies [13,16,23,30]. When
comparing two closely-related cell lines, it is expected that most of
Figure 4. Clinical validation analyses of the differential expression of Cul3 in bladder cancer progression. (A, B) Representative
immunohistochemistry expression patterns of Cul3 in non-invasive (A) and invasive (B) bladder tumors contained in tissue arrays. Strong expression
of Cul3 was observed in invasive bladder tumors when compared to non-invasive lesions. Cul3 can also be observed in the extracellular matrix in B.
There was a significant difference regarding the expression of Cul3 regarding tumor stage (p = 0.001: Original magnifications: x200). (C) Kaplan-Meier
curve survival analysis indicating that increased nuclear Cul3 protein expression assessed by immunohistochemistry in tissue arrays was significantly
associated with poor disease-specific survival (p = 0.002).
doi:10.1371/journal.pone.0053328.g004
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the proteins are expressed at similar levels. Indeed, most of the
SILAC ratios were within the 0.67–1.5 range, apart from those
related with the difference between these cells at their steady states
(that could be attributed to their different phenotype). In SILAC,
normalization was performed using the original mixture of the
cells at a 1:1 ratio and reaching 100% labeling efficiency for both
cell populations.
The limitation of selecting a threshold of expression to
consider proteins to be differentially expressed requires a follow-
up validation analysis for key data. Verification of changes by
two independent analytical methods, and using independent
in vitro strategies and clinical material provided confidence that
the experimental design permitted significant changes in
abundance to be validated. The limited correlation between
transcript and protein expression at their steady state was
similar to the 0.28 previously reported in pancreatic cells [14].
This could be attributed to the wider range of ratios of
expression measured by gene arrays while the majority of the
SILAC ratios were in the low range. SILAC ratios were more
limited due to the internal labelling and the characteristic 1:1
mixture of the protein extracts analyzed. The weak correlation
between the gene array and SILAC ratios highlighted the
relevance of quantitative proteomic approaches to estimate the
expression of proteins of interest (not always predictable based
on transcript levels), in concordance with previous reports [14].
There were missing data between both techniques because not
all the coding products of the genes measured by the early
version of the Affymetrix oligonucleotide array (U133A) were
detected by SILAC. Similarly, genes coding for the 831 proteins
identified by SILAC duplicates were not included among the
probes contained in the commercial U133 oligonucleotide array.
Availability of both transcript and protein expression levels
could also be utilized to uncover potential regulatory mecha-
nisms modifying translation or protein degradation. Immuno-
blotting validation was closely correlated to the SILAC results,
and also served to validate candidates identified in oligonucle-
otide arrays (Figure S2).
Cul3 was selected from the top over-expressed candidates in
T24T not previously characterized in bladder cancer for which we
had available reagents for further studies. Cul3 was differentially
expressed in T24T using three different methodologies: SILAC,
gene arrays and immunoblotting. Cul3 is one of the four members
of the cullin protein family [37,38]. It belongs to the core
component of multiple ubiquitin-protein ligase complexes that
Figure 5. Functional analyses of the impact of Cul3 silencing on: A) proliferation, B) migration, and C) invasion. The average of
duplicate experiments of each functional assay with siRNAs against Cul3 versus the control siRNA is represented in each panel. D) Immunoblotting of
proteins found differentially expressed by SILAC upon Cul3 silencing on T24T cells. The results suggested that the differential expression of several of
these proteins would be likely regulated by Cul3. Antibodies displaying a single predominant band at the expected molecular weights were
accepted: Cul3, Cullin 3; CAV1, Caveolin 1; FLNA, Filamin A; MSN, Moesin; EZR, Ezrin; NPM, Nucleophosmin; NUP133, Nucleoporin 133; IPO9. Importin
9; EGFR, Epidermal Growth Factor Receptor; GSN, Gelsolin; and a-tubulin, was used as the loading control.
doi:10.1371/journal.pone.0053328.g005
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mediate the ubiquitination and subsequent proteasomal degrada-
tion of their target proteins [39,40]. Cul3 acts as a scaffolding
protein in a heterodimeric complex playing a central role in the
specificity of polyubiquitinization of these proteins, positioning the
substrate and the ubiquitin-conjugating enzyme [38,41]. Although
the full list of targets whose ubiquitination and degradation is
mediated by Cul3 remains unknown, cancer-related proteins
reported include cyclin E [42], or Rho [43], among others [42–
45]. In concordance with the interaction network shown in Figure
S3, it could be proposed that Cul3 would be involved in the
proteasomal degradation of adhesion associated cytoskeletal
proteins such as filamin A, ezrin, caveolin1 or moesin. Indeed,
the expression of these proteins increased upon Cul3 silencing,
observations highlighting the impact of Cul3 expression not only
on the aggressive phenotype of T24T shown by functional assays,
but also modifying the expression of other proteins identified by
SILAC. It remains to be characterized whether Cul3 might be
directly involved in the proteasomal degradation of cytoskeleton
proteins, potentially regulating the migration and invasive
aggressiveness properties of T24T cells. Regarding therapeutic
implications, members of the cullin family are covalently modified
by NEDD8, where Cul3 ubiquitating ligase functioned as a
NEDD8-bound heterodimer [46]. Neddylation and deneddylation
may regulate Cul3 protein accumulation [47], suggesting new
approaches to treat cancer by inhibiting the NEDD8-activated-
cullin ligases [48]. To our knowledge, this is the first study
evaluating Cul3 by immunohistochemistry, not only in bladder
cancer but also in human tumors. Our findings were innovative
and clinically relevant since Cul3 expression was linked to the
invasive/metastatic phenotype in human bladder tumors, and also
revealed that this protein can be secreted to the extracellular
matrix. Our results highlighted the impact of the ubiquitin-
proteasome pathway in bladder cancer aggressiveness, uncovering
a novel biomarker and pathway potentially exploited therapeuti-
cally. Further focused designed studies are warranted to dissect the
clinical relevance of Cul3 expression patterns in specific bladder
cancer subgroups and address their specific clinical outcome
endpoints.
The proteomic approach identified differential expression of
proteins previously linked with aggressive clinical outcome in
bladder tumors: gelsolin [49], moesin [32], Ezrin [50], caveolin
[32], Filamin A [33]. The large number of differentially expressed
proteins localized to the cytoplasm highlighted the relevance of
adhesion molecules and cytoskeletal reorganization in bladder
cancer aggressiveness (suported also by the IPA analysis), which
could justify the higher proliferative, migration and invasive rate of
T24T. Cul3 was uncovered as a clinically and biologically relevant
candidate, which could promote cancer aggressiveness by regu-
lating the expression of other critical cancer-related proteins [48–
50]. Further research is warranted to define how cytoskeleton
remodelling of these proteins specifically contribute to bladder
cancer aggressiveness.
Concluding Remarks
The SILAC approach served to identify potential candidates
involved in bladder cancer aggressiveness in vitro. Functional and
clinical validation analyses served to uncover the roles of Cul3 at
regulating cytoskeleton remodelling, and as a progression and
clinical outcome stratification biomarker.
Supporting Information
Figure S1 Comparison of the metastatic profile using
gene profiling of a oligonucleotide array and SILAC. (A)
Dispersion plot of the ratios of expression (represented as circles)
observed between the oligonucleotide arrays and SILAC consid-
ering the 438 candidates defined by both techniques. The outliers
represent candidates with very high differential ratios by
oligonucleotide arrays (around 100) and SILAC (around 10). (B)
Dispersion plot of the ratios of expression (represented as circles)
observed between the oligonucleotide arrays and SILAC,
excluding the outliers with high expression in the oligonucleotide
arrays (.100) and in the SILAC (.9). Even after excluding the
outliers, while the range of expression of the ratios for
oligonucleotide microarrays was extensive, in SILAC analyses
the majority of the differential expression was mild in the low
range of ratios. (C) Cumulative probabilities (represented as
circles) of the observed differential expression ratio against the
expected ratio for oligonucleotide arrays. (A) Cumulative
probabilities (represented as circles) of the observed differential
expression ratio against the expected ratio for SILAC approach.
(PPT)
Figure S2 Western blotting validation of differentially
expressed proteins in T24T when compared to T24 on
the basis of the oligonucleotide arrays and that were not
quantified using SILAC. MMP2, Matrix Metalloproteinase 2;
EphA1, Ephrin type-A receptor 1; MAGE 1, Melanoma
associated antigen 1; IGFBP2, Insulin-like growth factor-binding
protein 2; SOX9, Transcription factor SOX-9; PMF-1, Poly-
amine-modulated factor 1; SIVA, Apoptosis regulatory protein
Siva; XRCC1, X-ray repair cross-complementing protein 1; ZYX,
Zyxin; RAB6, Ras-related protein 6; MMP1, Matrix Metallopro-
teinase 1; CK2, Cytokeratin 2; FGFR1, Fibroblast growth factor
receptor 1; CDK4, Cyclin-Dependent Kinase 4; REG1, Lithos-
tathine 1; CLDN3, Claudin 3; SDC, Syndecan; KISS1,
Metastasis-suppressor KiSS-1; SYP, Synaptophysin; SOX4, Tran-
scription factor SOX-4; ANXA1, Annexin A1; GGT-1, Gamma-
glutamyltranspeptidase 1; BDNF-1, Brain-derived neurotrophic
factor; NUP62, Nucleoporin 62; GAL3, Galectin 3; GRB2,
Growth factor receptor-bound protein 2; COX2, Cyclooxigen-
ase2. The antibodies were raised against the following protein (and
the dilutions used in immunoblots are shown): Annexin1 (38 kDa,
mouse, 1:2000, #610066, BD Transduction Laboratories), BDNF
(14–27 kDa, mouse, 1:50, #MAB248, R&D Systems, Minneap-
olis, MN, US), CDK4 (30 kDa, rabbit, 1:500, #SC-260, Santa
Cruz), Claudin-3 (22kDa, rabbit, 1:1000, #18-7340, Zymed,
Paisley, UK), Cox2 (70 kDa, mouse, 1:500, #35-8200, Zymed),
Cytokeratin 2 (66 kDa, mouse, 1:100, #65177, Progen Biotechnik
GmbH, Heidelberg), EphA1 (24 kDa, rabbit,1:50, #34-3300,
Zymed), FGF Receptor (110 kDa, mouse,1:100, #13-3100,
Zymed), Galectin-3 (18 kDa, rabbit, 1:40, #18-0393, Zymed),
GGT-1 (30–35 kDa, mouse, 1:200, #H00002678-M01, clone
1F9, Abnova), GRB2 (25kDa, mouse,#610112, BD Transduction
Laboratories) IGFBP-2 (35 kDa, mouse, 1:200, #MAB674, R&D
Systems), KISS1 (16 kDa, rabbit, 1:50, #3590, Biovision, CA,
USA), MAGE1 (46 kDa, mouse, 1:100, #MA454, Abcam,
Cambridge, UK), MMP1 (54 kDa, mouse, 1:2000, #IM35,
MERCK), MMP2 (64–72 kDa, mouse, 1:100, #MAB9021, clone
101721, R&D Systems), NUP62 (62 kDa, mouse, 1:100,
#N43620, BD Transduction Laboratories), PMF-1 (23 kDa,
mouse, 1:100, #P24620, BD Transduction Laboratories,), RAB6
(25 kDa, rabbit, 1:100, #SC-310, Santa Cruz), Reg1 (rabbit,
20 kDa, 1:1000 dilution, kindly supplied by Dr. Iovanna, located
at Inserm, Marseille, France), SOX9 (65 KDa, goat, 1:250,
#AF3075, R&D Systems,), SOX4 (40–46 kDa, mouse, 1:500,
#H00006659-A01, Abnova), Synaptophysin (38 kDa, rabbit,
1:100, #18-0130, Zymed), Syndecan (90 kDa, rabbit, 1:100,
#36-2900, Zymed), SIVA (37,5 kDa, goat, 1:1000, #HM1334,
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Hypromatrix, Worcester, MA), XRCC1 (70 kDa, mouse, 1:50,
#SC-56254, Santa Cruz), Zyxin (83 kDa, mouse, 1:100,
#Z45420, BD). Western Blots were scanned and analyzed using
a-tubulin as normalizing loading control.
(PPT)
Figure S3 Functional networks of the proteins identi-
fied: in silico protein interaction analysis. Molecular
network obtained using the IPA software selected from the
networks of differentially expressed proteins identified as it
contained the highest number of the proteins identified by SILAC
(n = 31). Addition of Cul3, the validated candidate, to this
molecular network served to generate an interaction map
connecting the novel candidate with other proteins identified
through their previously described biological interactions. In this
network, genes or gene products are represented as nodes, and the
biological relationship between two nodes is represented as an
edge. All edges are supported by at least one publication from the
information stored in the Ingenuity knowledge database.
(PPT)
Figure S4 Functional networks of the proteins identi-
fied: in silico protein interaction analysis. Biological
interaction networking highlighted on the map of the top ten
differentially expressed proteins in SILAC and oligonucleotide
arrays, and validated in Western blots, including Cul3. Accession
number and T24T/T24 ratio values for the proteins identified in
Table 1 were imported into IPA software to generate different
molecular networks. In this network, genes or gene products are
represented as nodes, and the biological relationship between two
nodes is represented as an edge. All edges are supported by at least
one publication from the information stored in the Ingenuity
knowledge database. The intensity of the node colour indicates the
degree of over- (red) or under- (green) expression in T24T when
compared to T24. The legend of the interaction network and the
relationships between molecules is also provided.
(PPT)
Table S1 Proteins with altered abundance in bladder
cancer metastatic cells. All proteins were identified at .99%
confidence (corresponding to a Mascot score .46). The table
includes accession number (gi), protein name, molecular weight (in
kD), gene array ratio, SILAC ratios and the standard deviation
(SD, n = 2). All proteins were identified in the two SILAC
replicates with at least two unique peptides. Proteins previously
described to be involved in cancer metastases are highlighted in
italics, while those reported to be related to bladder cancer
metastases are highlighted in bold.
(DOC)
Table S2 Protein ID and quantification. Proteins are listed
alphabetically according to Protein Name. Proteins were identified
according to the NCBI human databases (NCBI GI #s given for
each ID). The table includes the corresponding UniProt and IPI
accession numbers where available, Mascot scores corresponding
to the highest scoring occurrence of a given protein or peptide, and
GO annotations. T24T/T24 SILAC ratio = Intensity of the heavy
peptide (C13)/Intensity of the light peptide (C12).
(XLS)
Table S3 Detailed information of ratios obtained from
the proteins identified by SILAC (831 proteins, first
sheet) and those measured simultaneously by oligonu-
cleotide arrays (438 proteins, second sheet), including
probe identification and gene description of the oligo-
nucleotide arrays.
(XLS)
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